Related Experiment Video
Updated: Aug 6, 2026

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
Published on: March 24, 2017
Interferon regulatory factor 1 mediates ROS-dependent release of NETs in LPS-induced mouse pneumonia by interacting
Yandan Wei1, Wei Fu1, Yanxia Liu2
1Department of PICU, Huadu Maternal and Child Health Hospital of Guangzhou, Guangzhou, Guangdong Province, PR China.
Abstract:
While interferon regulatory factor 1 (IRF1) has been implicated in reactive oxygen species (ROS)-dependent neutrophil extracellular trap (NET) release during acute lung injury, its regulatory role in mitochondrial dysfunction-driven NETosis specific to pediatric pneumonia remains unexplored. Neutrophils were isolated from the bronchoalveolar lavage fluid (BALF) of pediatric pneumonia patients and the bone marrow of mice. IRF1 expression was quantified via qRT-PCR and Western blotting. Mitochondrial ROS (mtROS) and total ROS were measured by flow cytometry. Mitochondrial dysfunction was assessed by ATP quantification. NETosis was evaluated through immunofluorescence staining and ELISA quantification of neutrophil elastase (NE), myeloperoxidase-DNA (MPO-DNA), and citrullinated histone H3 (Cit-H3) levels. For in vivo studies, pneumonia-related lung injury was induced by intratracheal LPS instillation in mice, with pathological severity graded by H&E staining, pulmonary edema quantified via the wet/dry weight ratio, and inflammation assessed by the BALF protein concentration. Mechanistically, the IRF1/MMP9 interaction was predicted by bioinformatics (STRING database) and validated by co-immunoprecipitation (Co-IP) and immunofluorescence staining, while MMP9 overexpression was achieved via lentivirus transduction to delineate pathway regulation. IRF1 was significantly upregulated in BALF neutrophils from patients and correlated with elevated ROS production and mitochondrial dysfunction, as well as NETs release. IRF1 knockdown attenuated ROS-driven NETosis in vitro. Matrix metalloproteinase 9 (MMP9) was predicted to interact with IRF1, and MMP9 overexpression effectively reversed the beneficial effects of IRF1 deficiency on ROS release, mitochondrial dysfunction, neutrophil apoptosis, and NETosis. Consistently, in mouse models, MMP9 overexpression abolished the protective effects of IRF1 deficiency, exacerbating acute lung injury and restoring NETs levels in BALF.
Insights
Interferon regulatory factor 1 (IRF1) drives neutrophil extracellular trap (NET) release in pediatric pneumonia by promoting mitochondrial dysfunction and reactive oxygen species (ROS) production. Targeting the IRF1-matrix metalloproteinase 9 (MMP9) axis may offer therapeutic strategies for lung injury.
Area of Science:
- Immunology
- Cell Biology
- Pulmonology
Background:
- Interferon regulatory factor 1 (IRF1) is linked to reactive oxygen species (ROS)-dependent neutrophil extracellular trap (NET) release in acute lung injury.
- The specific role of IRF1 in mitochondrial dysfunction-driven NETosis in pediatric pneumonia is not understood.
Purpose of the Study:
- To investigate the role of IRF1 in mitochondrial dysfunction and NETosis in pediatric pneumonia.
- To elucidate the underlying mechanisms involving ROS and matrix metalloproteinase 9 (MMP9).
Main Methods:
- Neutrophils were isolated from pediatric pneumonia patients and mice.
- IRF1 expression, ROS levels, mitochondrial function, and NETosis markers were quantified.
- In vivo mouse models of pneumonia were used to assess lung injury.
- IRF1-MMP9 interaction was studied using bioinformatics, co-immunoprecipitation, and immunofluorescence.
Main Results:
- IRF1 was upregulated in neutrophils from pediatric pneumonia patients, correlating with increased ROS, mitochondrial dysfunction, and NETosis.
- IRF1 knockdown reduced ROS-driven NETosis in vitro.
- MMP9 overexpression reversed the protective effects of IRF1 deficiency, exacerbating lung injury in vivo.
Conclusions:
- IRF1 plays a critical role in promoting mitochondrial dysfunction and NETosis in pediatric pneumonia.
- The IRF1-MMP9 interaction is a key pathway in the pathogenesis of pneumonia-related lung injury.
- Modulating the IRF1-MMP9 axis could be a therapeutic target for pediatric pneumonia.
